Your session is about to expire
← Back to Search
ETR028 + ETR029 for Acute Pain
Study Summary
This trial is testing the safety and tolerability of two new drugs relative to a comparator drug, hydrocodone bitartrate hemipentahydrate. The trial will test subjects under both fasted and fed conditions, with naltrexone blockade.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Logistics
Participation is compensated
You will be compensated for participating in this trial.
Who is running the clinical trial?
Frequently Asked Questions
Has the FDA confirmed permission for A2. <=60mg ETR028?
"Due to the lack of data on A2. <=60mg ETR028's efficacy and safety, our team at Power gave this drug a rating of 1 out of 3."
Does this research encompass individuals aged 35 and older?
"This trial's prerequisite for entry is that the participant should be between 18 to 55 years of age. However, there are 20 more trials specifically designed for minors and 116 options available for seniors above 65."
Are there any opportunities for participants in this trial at present?
"Data hosted on clinicaltrials.gov attests that this medical trial, which commenced on September 27th 2022, is actively enrolling participants. The study's information was most recently modified in October 7th of the same year."
What is the aggregate size of the population involved in this clinical investigation?
"Affirmative. According to clinicaltrials.gov, this study is currently recruiting participants who meet the criteria. It was initially posted on September 27th 2022 and has been recently updated as of October 7th 2022. A total of 78 subjects are needed across 1 site for this trial."
Share this study with friends
Copy Link
Messenger